Treatment of ANCA-associated vasculitis: New therapies and a look at old entities

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis that primarily comprises 2 clinical syndromes: granulomatosis with polyangiitis and microscopic polyangiitis. Cyclophosphamide and glucocorticoids have traditionally been used for induction of remission. However, more recent studies have shown that rituximab is as effective as cyclophosphamide for induction therapy in patients with newly diagnosed severe AAV and superior for patients with relapsing AAV. There is also accumulating evidence indicating a potential role of rituximab for maintenance therapy in AAV. In this article, we will review the evidence supporting the various treatment choices for patients with AAV.

Original languageEnglish (US)
Pages (from-to)182-193
Number of pages12
JournalAdvances in Chronic Kidney Disease
Volume21
Issue number2
DOIs
StatePublished - Mar 2014

Fingerprint

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Cyclophosphamide
Microscopic Polyangiitis
Therapeutics
Remission Induction
Granulomatosis with Polyangiitis
Vasculitis
Glucocorticoids

Keywords

  • ANCA-associated vasculitis
  • Cyclophosphamide
  • Rituximab

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{06e4b9116a6746a49e15ff288cbe1ef1,
title = "Treatment of ANCA-associated vasculitis: New therapies and a look at old entities",
abstract = "Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis that primarily comprises 2 clinical syndromes: granulomatosis with polyangiitis and microscopic polyangiitis. Cyclophosphamide and glucocorticoids have traditionally been used for induction of remission. However, more recent studies have shown that rituximab is as effective as cyclophosphamide for induction therapy in patients with newly diagnosed severe AAV and superior for patients with relapsing AAV. There is also accumulating evidence indicating a potential role of rituximab for maintenance therapy in AAV. In this article, we will review the evidence supporting the various treatment choices for patients with AAV.",
keywords = "ANCA-associated vasculitis, Cyclophosphamide, Rituximab",
author = "Ladan Zand and Ulrich Specks and Sethi, {Sanjeev M} and Fervenza, {Fernando Custodio}",
year = "2014",
month = "3",
doi = "10.1053/j.ackd.2014.01.009",
language = "English (US)",
volume = "21",
pages = "182--193",
journal = "Advances in Chronic Kidney Disease",
issn = "1548-5595",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Treatment of ANCA-associated vasculitis

T2 - New therapies and a look at old entities

AU - Zand, Ladan

AU - Specks, Ulrich

AU - Sethi, Sanjeev M

AU - Fervenza, Fernando Custodio

PY - 2014/3

Y1 - 2014/3

N2 - Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis that primarily comprises 2 clinical syndromes: granulomatosis with polyangiitis and microscopic polyangiitis. Cyclophosphamide and glucocorticoids have traditionally been used for induction of remission. However, more recent studies have shown that rituximab is as effective as cyclophosphamide for induction therapy in patients with newly diagnosed severe AAV and superior for patients with relapsing AAV. There is also accumulating evidence indicating a potential role of rituximab for maintenance therapy in AAV. In this article, we will review the evidence supporting the various treatment choices for patients with AAV.

AB - Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis that primarily comprises 2 clinical syndromes: granulomatosis with polyangiitis and microscopic polyangiitis. Cyclophosphamide and glucocorticoids have traditionally been used for induction of remission. However, more recent studies have shown that rituximab is as effective as cyclophosphamide for induction therapy in patients with newly diagnosed severe AAV and superior for patients with relapsing AAV. There is also accumulating evidence indicating a potential role of rituximab for maintenance therapy in AAV. In this article, we will review the evidence supporting the various treatment choices for patients with AAV.

KW - ANCA-associated vasculitis

KW - Cyclophosphamide

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84896900502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896900502&partnerID=8YFLogxK

U2 - 10.1053/j.ackd.2014.01.009

DO - 10.1053/j.ackd.2014.01.009

M3 - Article

C2 - 24602467

AN - SCOPUS:84896900502

VL - 21

SP - 182

EP - 193

JO - Advances in Chronic Kidney Disease

JF - Advances in Chronic Kidney Disease

SN - 1548-5595

IS - 2

ER -